tag:blogger.com,1999:blog-56573627885074216312024-02-19T02:37:19.914+01:00Tolosako Osasun ZentroaEbidentzian oinarritutako osasungintzaren (EOO)irakaskuntza eta praktika uztartzeko asmoarekin sortutako bloga .Bide batez , euskera sustatzeko asmo xumea.Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.comBlogger176125tag:blogger.com,1999:blog-5657362788507421631.post-11386348989160363292018-09-01T00:12:00.000+02:002018-09-01T00:12:10.228+02:00AGURRA <span style="font-family: Verdana, sans-serif;">Gabon denoi :</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">Aro berri bat iritsi zaigu 2010ean blog honen egitasmoarekin hasi ginen gehienoi.</span><br />
<span style="font-family: Verdana, sans-serif;">Batetik, batzuek erretretara heldu dira edo urte hauetan Tolosako Osasun zentroan jardun duten batzuk beste osasun zentroetan ari dira gaur egun </span><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;">eta bestetik</span>, lehen arretako, jakina den, lana ugaritzeak asko zaildu </span><span style="font-family: Verdana, sans-serif;">du </span><span style="font-family: Verdana, sans-serif;">trasmisioa egitea lantalde berria sortzeko . Hori dela eta, bukaera eman nahi diogu urte hauetan talde lan abesgarriaren adierazle den blog honi.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;">Eskerrak eman nahi dizkizuegu jarraitzaile guztiei <table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgVA7qYLBuhA5GMl43vkkEAGcHVNDSRyeBuUIka37JBQwhPw0i77pp-rxcSHvFoId-UgBdtcC9Q5urUnlvGjZkzP_qGwfImvyokVCu4sQPs3pGr9dVsqpfV3Rox_iuZoHAQ6mLhRQDvU1Q/s1600/Agurra.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="745" data-original-width="800" height="298" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgVA7qYLBuhA5GMl43vkkEAGcHVNDSRyeBuUIka37JBQwhPw0i77pp-rxcSHvFoId-UgBdtcC9Q5urUnlvGjZkzP_qGwfImvyokVCu4sQPs3pGr9dVsqpfV3Rox_iuZoHAQ6mLhRQDvU1Q/s320/Agurra.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="http://www.exprai.com/2010/04/bigarren-sarrera-eta-bukatzeko-asmoz.html" target="_blank">marrazkia hemendik lortu dugu </a></td></tr>
</tbody></table>
</span>Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com2tag:blogger.com,1999:blog-5657362788507421631.post-82269647842314471962018-05-29T23:13:00.002+02:002018-05-29T23:13:41.577+02:00BGBK kasuan tratamendu hirukoitza (Kortk+LAMA+LABA) , bikoitza(Kortik+LABA edo LAMA+LAMA) baina hobea da?<br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgWSpr92OL7dq1i8LaFDPo70CW-bW1moGfBeJd_8mAq_lVZc_y88_VgB33exFmDqIe4gd1jZPnmbLVzw6C8mGX7sSzhDypPf8xIgNQRj7jbgL7iXsdP6nm62vHLRrUGiwd1vfsD1NqO5_M/s1600/%25C3%25ADndice.jpg" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="194" data-original-width="259" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgWSpr92OL7dq1i8LaFDPo70CW-bW1moGfBeJd_8mAq_lVZc_y88_VgB33exFmDqIe4gd1jZPnmbLVzw6C8mGX7sSzhDypPf8xIgNQRj7jbgL7iXsdP6nm62vHLRrUGiwd1vfsD1NqO5_M/s1600/%25C3%25ADndice.jpg" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="https://es.slideshare.net/pgramos/dispositivo-spiromax-en-busca-del-inhalador-ideal" target="_blank"><span style="font-family: "verdana" , sans-serif;">Marrazkia hemendik lortu dugu </span></a></td></tr>
</tbody></table>
<br />
<span style="font-family: Verdana, sans-serif;">Lipson DA eta laguntzaileek, GlaxoSmithKline-ren babespean, <a href="https://www.ncbi.nlm.nih.gov/pubmed/29668352" target="_blank">IMPACT entsegua</a> argitaratu dute , non , Bronkioetako gaixotasun butzatzailea duteten artean , hiru botika batera dituen inhaladoreak (Kortik+LAMA+LABA) , bi botika duen inhaladorearekin alderatuta (Kortik+LAMA edo LAMA+LABA), lehenengoaren aldeko apustua egiten dute, gaizkitze kopurua gutxitzen duelako, hori bai, neumonia kasu gehiago sortuz ere.</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">Pazienteak(P) 10.355 , gehienek larritze bat baina gehiago izan dutenak aurreko urtean (1: %45ek 2 :%43k 3 <u>⥸</u>:%11k).Antzekoak dira, ikerketako 3 adarretako pazienteak)</span><br />
<br />
<span style="font-family: Verdana, sans-serif;">Jarraipena :52 aste</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">Tratamendu uzteen kopuru nabarmena da hiru taldeetan( %18,%25 eta %27); Honen zergatiari buruzko azalpen berezirik ez dute eman autoreek</span><br />
<br />
<span style="font-family: Verdana, sans-serif;">Interbentzioa(I) Tratamendu hirukoitza (Kortk+LAMA+LABA)</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">Alderatzailea (C) Tratamendu bikoitza </span><br />
<ul>
<li><span style="font-family: Verdana, sans-serif;"> Kortik+LABA (Fluticasona Fuoratoa 100µg +Vilanterola 25µg) </span></li>
<li><span style="font-family: Verdana, sans-serif;"> LAMA+LABA (Umeklidinioa 62µg+Vilanterola 25µg) </span></li>
</ul>
<span style="font-family: Verdana, sans-serif;">Emaitzak (O)</span><br />
<ul>
<li><span style="font-family: Verdana, sans-serif;"><b> Urteko larritze tasa </b> 0.91 vs 1.07 </span></li>
</ul>
<span style="font-family: Verdana, sans-serif;"> </span><span style="font-family: Verdana, sans-serif;"> 0.91 vs 1.21 </span><br /><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;"> </span><span style="font-family: Verdana, sans-serif;">Lehenengo larritze gertakaria duten pazienteen kopurua kontuan hartuta,</span></span><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;">AE (RR) 0.85(0.80-0.90) eta </span></span><span style="font-family: Verdana, sans-serif;"> 0.75(0.70-0.81)</span><br /><span style="font-family: Verdana, sans-serif;"><i><span style="font-size: x-small;">Zenbaki absolutuak ematen ez dituztenez, ezin izan dugu TTK-k kalkulatu </span></i> </span><span style="font-family: Verdana, sans-serif;"></span><br />
<ul>
<li><span style="font-family: Verdana, sans-serif;"></span><span style="font-family: Verdana, sans-serif;"><b>Larritze ondoriozko ospitaleratze tasa</b> </span><span style="font-family: Verdana, sans-serif;"></span></li>
</ul>
<span style="font-family: Verdana, sans-serif;"> </span><span style="font-family: Verdana, sans-serif;">0.13 vs 0.19 (Umeklidinio+Vilanterola) </span><br />
<span style="font-family: Verdana, sans-serif;"> Ospitaleratze paziente kopurua kontutan hartuta, AE 0.66 (0.56-0.78)</span><br />
<span style="font-family: Verdana, sans-serif;"> </span><br />
<br />
<ul>
<li><span style="font-family: Verdana, sans-serif;"> <b>Neumoniak</b> Hirukoitza vs LAMA+LABA HR 1.53(1.22-1.92) </span></li>
</ul>
<br />
<span style="font-family: Verdana, sans-serif;"><span style="color: blue;">Urtebetean 0.91 , 1.07 edo 1.21 larritze kopuruen ezberdintasun honek merezi duela uste duzue? Ez ahaztu Neumonia kasuak ere areagozten dituela tratamendu hirukoitzak</span> </span><br />
<span style="font-family: Verdana, sans-serif;"> </span>Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com1tag:blogger.com,1999:blog-5657362788507421631.post-31904797131765883822018-04-21T21:55:00.002+02:002018-04-23T22:25:08.279+02:00PISUA GALTZEAK HILKORTASUN OROKORRA GUTXITZEN DU.<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:HyphenationZone>21</w:HyphenationZone>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]--><br />
<!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]--><!--[if !mso]><img src="https://img1.blogblog.com/img/video_object.png" style="background-color: #b2b2b2; " class="BLOGGER-object-element tr_noresize tr_placeholder" id="ieooui" data-original-id="ieooui" />
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Tabla normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1"/>
</o:shapelayout></xml><![endif]-->
<br />
<div class="H2">
<span lang="EU" style="mso-ansi-language: EU;"><br /></span></div>
<div class="H2">
<br /></div>
<table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse: collapse; margin-left: 1.15pt; mso-padding-alt: 0cm 0cm 0cm 0cm; mso-table-layout-alt: fixed;">
<tbody>
<tr style="mso-yfti-firstrow: yes; mso-yfti-irow: 0; mso-yfti-lastrow: yes;">
<td style="border: ridge windowtext 2.25pt; mso-border-alt: three-d-emboss windowtext 2.25pt; padding: 0cm 0cm 0cm 0cm; width: 375.0pt;" width="500"><div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU;">P<span style="color: red;"><span style="color: black;">ISUA
GALTZEAK</span></span> </span></span><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU;">(GANTZ ASEAK ELIKADURAN GUTXITUZ)</span></span>HILKORTASUN OROKORRA GUTXIT<span style="font-family: "verdana" , sans-serif;">ZEN DU.</span></span></span><br />
<span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU;"><span style="font-family: "verdana" , sans-serif;">HALA ERE</span> EZ DU BIHOTZ-HODIETAKO
HILKORTASUNIK EZTA MINBIZIAK ERAGINDAKO HILKORTASUNIK</span></span><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU;"> GUTXITZEN</span></span>.</span></span></div>
</td>
</tr>
</tbody></table>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Erreferentzia:</span></b></div>
<pre><i style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "times new roman"; font-size: 12.0pt;">Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, Sharma P, Fraser</span></i></pre>
<pre><i style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "times new roman"; font-size: 12.0pt;">C, MacLennan G. Effects of weight loss interventions for adults who are obese on </span></i></pre>
<pre><i style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "times new roman"; font-size: 12.0pt;">mortality, cardiovascular disease, and cancer: systematic review and</span></i></pre>
<pre><i style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "times new roman"; font-size: 12.0pt;">meta-analysis. BMJ. 2017 Nov 14;359:j4849. doi: 10.1136/bmj.j4849. Review. PubMed</span></i></pre>
<pre><i style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="font-family: "times new roman"; font-size: 12.0pt;">PMID: 29138133; PubMed Central PMCID: PMC5682593.</span></i></pre>
<div class="MsoNormal">
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqMdduCgv1CFvlhT5yaJn7gypQMJx822c1G0Oqiy-HX9Hc7EQ0r2Oa3Qzz21yxsth9do3RzK2njhSSTCVkSrzPDiHCpCGK64ZdppBWrDWO4hjMm3At0RxqSn8cqzTwF24_BRJ7gYNwSW0/s1600/crossfit-para-bajar-peso.jpg" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="451" data-original-width="800" height="112" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqMdduCgv1CFvlhT5yaJn7gypQMJx822c1G0Oqiy-HX9Hc7EQ0r2Oa3Qzz21yxsth9do3RzK2njhSSTCVkSrzPDiHCpCGK64ZdppBWrDWO4hjMm3At0RxqSn8cqzTwF24_BRJ7gYNwSW0/s200/crossfit-para-bajar-peso.jpg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="https://www.sinburpeesenmiwod.com/ejercicios-de-crossfit-para-bajar-peso/" target="_blank"><span style="font-family: "verdana" , sans-serif;">Argazkia hemendik lortu dugu</span></a></td></tr>
</tbody></table>
<span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"></span></span></span><br />
<span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;">
<b style="mso-bidi-font-weight: normal;">Egile nagusiaren posta elektronikoa: </b></span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><i style="mso-bidi-font-style: normal;"><span lang="EN-GB" style="layout-grid-mode: both; mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">a.avenell@abdn.ac.uk</span></i></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Galdera hiru osagaiez:</span></b><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"> </span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><u><span lang="PT-BR" style="mso-ansi-language: PT-BR; mso-bidi-font-size: 12.0pt;">Gaixoak</span></u><span lang="PT-BR" style="mso-ansi-language: PT-BR; mso-bidi-font-size: 12.0pt;">: IMC≥30. 18 URTE BAINO GEHIAGO.</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><u><span lang="PT-BR" style="mso-ansi-language: PT-BR; mso-bidi-font-size: 12.0pt;">Interbentzioa:</span></u><span lang="PT-BR" style="mso-ansi-language: PT-BR; mso-bidi-font-size: 12.0pt;"> Dieta hipokalorikoa
(gantz ase gutxikoa) vs kontrola.</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="PT-BR" style="mso-ansi-language: PT-BR; mso-bidi-font-size: 12.0pt;">Emaitzak: Hilkortasun orokorra, bihotz-hodietako
hilkortasuna,<span style="color: red;"> <span style="color: black;">minbiziarengatiko heriotza.</span></span></span></span></span></div>
<div class="MsoNormal" style="margin: 0cm;">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><br style="mso-special-character: line-break;" />
<br style="mso-special-character: line-break;" />
</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Berrazterketa:</span></b></span></span></div>
<div class="MsoNormal" style="mso-layout-grid-align: none; text-autospace: none;">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Bibliografia iturriak</span></b><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"> : </span></span></span></div>
<div style="mso-element-anchor-horizontal: margin; mso-element-frame-hspace: 7.05pt; mso-element-top: 12.65pt; mso-element-wrap: around; mso-element: frame; mso-height-rule: exactly;">
<table align="left" cellpadding="0" cellspacing="0" hspace="0" vspace="0">
<tbody>
<tr>
<td align="left" style="padding: 0cm 7.05pt;" valign="top"><div class="MsoNormal" style="mso-element-anchor-horizontal: margin; mso-element-frame-hspace: 7.05pt; mso-element-top: 12.65pt; mso-element-wrap: around; mso-element: frame; mso-height-rule: exactly;">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="PT-BR" style="mso-ansi-language: PT-BR; mso-bidi-font-size: 12.0pt;">Medline, Embase, and the Cochrane Central
Register of Controlled Trials, from 1966 to December 2015.</span></span></span></div>
<div class="MsoNormal" style="mso-element-anchor-horizontal: margin; mso-element-frame-hspace: 7.05pt; mso-element-top: 12.65pt; mso-element-wrap: around; mso-element: frame; mso-height-rule: exactly;">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="PT-BR" style="mso-ansi-language: PT-BR; mso-bidi-font-size: 12.0pt;">Ez dago hizkuntza murrizketarik.</span></span></span></div>
<div class="MsoNormal" style="mso-element-anchor-horizontal: margin; mso-element-frame-hspace: 7.05pt; mso-element-top: 12.65pt; mso-element-wrap: around; mso-element: frame; mso-height-rule: exactly;">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="PT-BR" style="mso-ansi-language: PT-BR; mso-bidi-font-size: 12.0pt;">Egileekin harremanetan jarri dira.</span></span></span></div>
</td>
</tr>
</tbody></table>
</div>
<div class="MsoNormal" style="mso-layout-grid-align: none; text-autospace: none;">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="PT-BR" style="font-family: "arial"; font-size: 10.0pt;">Argitaratuak
ez dauden ikerketak</span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="PT-BR" style="font-family: "arial"; font-size: 10.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="PT-BR" style="font-family: "arial"; font-size: 10.0pt;"> ere</span></span></span> bilatzen saiatu dira .</span><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"> </span></b></span></span><br />
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Azterlanen hautaketa</span></b><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">: <span style="mso-spacerun: yes;"> </span></span><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">Ausazko saiakuntza klinikoak (ASK).</span><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><br style="mso-special-character: line-break;" />
<br style="mso-special-character: line-break;" />
</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Sartutako datuen
ezaugarriak</span></b><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">:.</span></span></span></div>
<table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse: collapse; margin-left: 1.15pt; mso-padding-alt: 0cm 0cm 0cm 0cm; mso-table-layout-alt: fixed;">
<tbody>
<tr style="mso-yfti-firstrow: yes; mso-yfti-irow: 0;">
<td style="border: 2.25pt ridge; padding: 0cm; width: 352.35pt;" width="470"><div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Berrazterle bereiziak al daude</span></span></span></div>
</td>
<td style="border: 2.25pt ridge; padding: 0cm; width: 24pt;" width="32"><div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">BAI</span></span></span></div>
</td>
</tr>
<tr style="mso-yfti-irow: 1; mso-yfti-lastrow: yes;">
<td style="border: 2.25pt ridge; padding: 0cm; width: 352.35pt;" width="470"><div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Heterogenetasuneko azterketa?</span></span></span></div>
</td>
<td style="border-color: currentcolor; border-style: none ridge ridge none; border-width: medium 2.25pt 2.25pt medium; padding: 0cm; width: 24pt;" width="32"><div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">BAI</span></span></span></div>
</td>
</tr>
</tbody></table>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><br /></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Ebidentzia:</span></b></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><u><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Emaitzak:</span></u></b></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">54 ASK. N=30206.</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">%27,8 kalitate onekoak dira.</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">% 13 kalitate txarrekoak dira.</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">GRADE sistemarekin aztertu dute </span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">kalitatea</span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">. Ez dago
heterogeneotasunik.</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">HILKORTASUN OROKORRA: RR 0,82(0,71-0,95). Kalitate
altua. Tratatu beharreko kopurua (TBK) 155 (96-558). </span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EN-GB" style="mso-ansi-language: EN-GB; mso-bidi-font-size: 12.0pt;">BIHOTZ-HODIETAKO HILKORTASUNA: RR 0,93(0,67-1,31). </span><span lang="IT" style="mso-ansi-language: IT; mso-bidi-font-size: 12.0pt;">Kalitate
ertaina.</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="IT" style="mso-ansi-language: IT; mso-bidi-font-size: 12.0pt;">MINBIZIARENGATIKO HERIOTZA: RR 0,58(0,30-1,11). Kalitate baxua.</span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="IT" style="mso-ansi-language: IT; mso-bidi-font-size: 12.0pt;">Saiakuntza kliniko batek dauka (</span><span lang="IT" style="layout-grid-mode: both; mso-ansi-language: IT; mso-bidi-font-size: 12.0pt;">Look AHEAD) pisu gehien ikerketan. Bataz besteko,</span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="IT" style="layout-grid-mode: both; mso-ansi-language: IT; mso-bidi-font-size: 12.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="IT" style="layout-grid-mode: both; mso-ansi-language: IT; mso-bidi-font-size: 12.0pt;">urtero</span></span></span> 3 kilo jaistearekin
lortzen dira </span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="IT" style="layout-grid-mode: both; mso-ansi-language: IT; mso-bidi-font-size: 12.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="IT" style="layout-grid-mode: both; mso-ansi-language: IT; mso-bidi-font-size: 12.0pt;">emaitza hauek.</span></span></span></span></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-indent: 36pt;">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><br /></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Iruzkina: </span></b></span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Azterketa sistematikoa kalitate onekoa da. Hilkortasun orokorra aztertzen
duten saikuntza klinikoak kalitate onekoak dira. Eragingortasuna nabarmentzeko,pertsona askori ezarri
behar zaio neurria, kasu honetan pisu galera; </span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">guztiek loditasuna
daukatenez eta 3 kg
urtero jaitsi beharrak</span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"> </span></span></span></span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"> h</span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">ilkortasuna gutxitzen duel</span></span></span>a kontutan hartuz</span></span></span></span></span></span><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">,</span></span></span> </span></span></span>neurria ezartzeak merezi duela esan dezakegu.</span></span></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;"><span style="mso-tab-count: 1;"> </span></span></div>
<div class="MsoNormal">
<span style="font-size: x-small;"><span style="font-family: "verdana" , sans-serif;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">Jorratzailea</span></b><span lang="EU" style="mso-ansi-language: EU; mso-bidi-font-size: 12.0pt;">: Mikel Moreno (<a href="mailto:mmorenob@cfnavarra.es">mmorenob@cfnavarra.es</a>)
<br />
<b style="mso-bidi-font-weight: normal;">Data: 2018/4/17.</b></span></span></span></div>
Unknownnoreply@blogger.com2tag:blogger.com,1999:blog-5657362788507421631.post-55795919010538125472018-04-12T08:34:00.002+02:002018-04-13T07:54:25.209+02:00KANAGLIFLOZINA ETA ARRISKU KARDIOBASKULARRA<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:HyphenationZone>21</w:HyphenationZone>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
</w:Compatibility>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
</w:WordDocument>
</xml><![endif]-->
<br />
<div align="center" class="MsoNormal" style="text-align: center;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">KANAGLIFLOZINA EZ DA ERAGINKORRA LEHEN MAILAKO
PREBENTZIOAN 2 MOTAKO DIABETIKOETAN. BIGARREN MAILAKO PREBENTZIOAN
ERAGINKORTASUN TXIKIA DAUKA ETA KONTRAKO ERAGINAK MAIZ SORTZEN DITU</span></b></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh1OQgAM7SFyf3V5nkLt4j7RosiyEfuaYmCIcLqcxkcuklOacoFl_uVSNM64WnxfBd5eluURPsaxQuIuIqD5mBvnMkuKmF_9ZRN4yciOklTZtmE7gQ6A4b4BjvZ5FaPjPEUG8QhC5zUrzs/s1600/CANVAS.png" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="225" data-original-width="471" height="152" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh1OQgAM7SFyf3V5nkLt4j7RosiyEfuaYmCIcLqcxkcuklOacoFl_uVSNM64WnxfBd5eluURPsaxQuIuIqD5mBvnMkuKmF_9ZRN4yciOklTZtmE7gQ6A4b4BjvZ5FaPjPEUG8QhC5zUrzs/s320/CANVAS.png" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="http://www.siacardio.com/editoriales/prevencion-cardiovascular/estudio-canvas-canagliflozina-en-diabetes-y-eventos-cardiovasculares/" target="_blank"><span style="font-family: "verdana" , sans-serif; font-size: xx-small;">Ikurra hemendik lortu dugu</span></a></td></tr>
</tbody></table>
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
<div class="MsoNormal" style="text-align: left;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
<div class="MsoNormal" style="text-align: left;">
<!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Tabla normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
table.MsoTableGrid
{mso-style-name:"Tabla con cuadrícula";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-border-insideh:.5pt solid windowtext;
mso-border-insidev:.5pt solid windowtext;
mso-para-margin-top:5.0pt;
mso-para-margin-right:0cm;
mso-para-margin-bottom:5.0pt;
mso-para-margin-left:0cm;
mso-pagination:none;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]--></div>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> </span></b></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";">Erreferentzia</span></b><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"> :</span><span lang="EU" style="mso-ansi-language: EU;"> </span><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU;">Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W,</span></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU;">Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group. </span><span lang="EN-GB" style="font-family: "arial"; mso-ansi-language: EN-GB;"> </span></span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EN-GB" style="font-family: "arial"; mso-ansi-language: EN-GB;">Canagliflozin for Primary and Secondary Prevention of Cardiovascular</span><span lang="EN-GB" style="font-family: "arial"; mso-ansi-language: EU;"> </span><span lang="EN-GB" style="font-family: "arial"; mso-ansi-language: EN-GB;">Events: </span></span></pre>
<pre><span lang="EN-GB" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EN-GB;">Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). </span></pre>
<pre><span lang="EN-GB" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EN-GB;">Circulation. 2018 Jan 23;137(4):323-334. doi:10.1161/CIRCULATIONAHA.117.032038. </span></pre>
<pre><span lang="EN-GB" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EN-GB;">Epub 2017 Nov 13. </span></pre>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EN-GB" style="font-family: "arial"; mso-ansi-language: EN-GB;">PubMed PMID: 29133604;</span><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU;"></span></span></pre>
<pre><span lang="EN-GB" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EN-GB;">PubMed Central PMCID: PMC5777572.</span></pre>
<div class="MsoNormal">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small;"><br style="mso-special-character: line-break;" />
<br style="mso-special-character: line-break;" />
</span></div>
<pre><span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Courier New";"><span style="mso-spacerun: yes;"></span>Egileak eta helbidea: </span></b><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU;">Kenneth W. Mahaffey, MD</span></span></pre>
<pre><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU;">E-mail <a href="mailto:kenneth.mahaffey@stanford.edu">kenneth.mahaffey@stanford.edu</a></span></pre>
<pre><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU;"> </span></pre>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU"><span style="mso-spacerun: yes;"> </span>Galdera bere hiru
osagaiekin:</span></b><span lang="EU"> </span></span></div>
<table border="0" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="border-collapse: collapse; mso-padding-alt: 0cm 0cm 0cm 0cm;">
<tbody>
<tr style="mso-yfti-firstrow: yes; mso-yfti-irow: 0;">
<td style="border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt; width: 108.05pt;" valign="top" width="144"><div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b><i><span lang="EU">Gaixoak</span></i></b></span></div>
</td>
<td style="border-left: none; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt; width: 108.05pt;" valign="top" width="144"><div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b><i><span lang="EU">Interbentzioa</span></i></b></span></div>
</td>
<td style="border-left: none; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt; width: 108.05pt;" valign="top" width="144"><div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b><i><span lang="EU">Alderaketa</span></i></b></span></div>
</td>
<td style="border-left: none; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt; width: 108.05pt;" valign="top" width="144"><div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b><i><span lang="EU">Emaitzetako aldagaia</span></i></b></span></div>
</td>
</tr>
<tr style="mso-yfti-irow: 1; mso-yfti-lastrow: yes;">
<td style="border-top: none; border: solid windowtext 1.0pt; padding: 0cm 5.4pt 0cm 5.4pt; width: 108.05pt;" valign="top" width="144"><div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;">2 motako diabetikoak:</span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span lang="EN-GB" style="font-family: "verdana" , sans-serif; font-size: x-small;">-Lehen
mailako prebentzioko taldea: Arrisku kardiobaskular handia.</span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span lang="EN-GB" style="font-family: "verdana" , sans-serif; font-size: x-small;">-Bigarren
mailako prebentzioko taldea: bihotz-hodietako gaixotasuna eduki dutenak.</span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt; width: 108.05pt;" valign="top" width="144"><div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EU">Kanagliflozina 100mg eta 300mg.</span></span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt; width: 108.05pt;" valign="top" width="144"><div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EU">Plazeboa</span></span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; padding: 0cm 5.4pt 0cm 5.4pt; width: 108.05pt;" valign="top" width="144"><div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; mso-pagination: widow-orphan;">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small;">-Bihotz-hodietako hilkortasuna, miokardioko
infartua, garuneko hodietako istripua.</span></div>
</td>
</tr>
</tbody></table>
<div class="MsoNormal">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small;"><br style="mso-special-character: line-break;" />
<br style="mso-special-character: line-break;" />
</span></div>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU">Ikerketa:</span></b></span><br />
<b style="font-family: Verdana, sans-serif; font-size: small;">Gaixoak :</b></div>
<div class="MsoNormal">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small;">Lehen mailako prebentzio taldea:</span></b></div>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU">Kontrol taldea</span></b><span lang="EU"> (N =<span style="mso-spacerun: yes;"> </span>2039).</span></span></div>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU">Esperimental taldea</span></b><span lang="EU"> (N = 1447).</span></span></div>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
<div class="MsoNormal">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small;">Bigarren mailako prebentzio taldea:</span></b></div>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU">Kontrol taldea</span></b><span lang="EU"> (N =<span style="mso-spacerun: yes;"> </span>2900).</span></span></div>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU">Esperimental taldea</span></b><span lang="EU"> (N = 3756).</span></span></div>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
<div class="H5" style="mso-outline-level: body-text; page-break-after: auto;">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">Emaitzak:</span></div>
<table border="1" cellpadding="0" cellspacing="0" class="MsoTableGrid" style="border-collapse: collapse; border: none; mso-border-alt: solid windowtext .5pt; mso-border-insideh: .5pt solid windowtext; mso-border-insidev: .5pt solid windowtext; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt; mso-yfti-tbllook: 480;">
<tbody>
<tr style="mso-yfti-firstrow: yes; mso-yfti-irow: 0;">
<td style="border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
</td>
<td style="border-left: none; border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
</td>
<td style="border-left: none; border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
</td>
<td style="border-left: none; border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">HR</span></b></div>
</td>
<td style="border-left: none; border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">NNT/NNH</span></b></div>
</td>
</tr>
<tr style="mso-yfti-irow: 1;">
<td rowspan="3" style="border-top: none; border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">LEHEN MAILAKO PREBENTZIO TALDEA</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">ALDAGAI KONBINATUA</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">0.98 (0.74</span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-GB" style="font-family: GandhariUnicode-Roman; mso-ansi-language: EN-GB; mso-bidi-font-family: GandhariUnicode-Roman; mso-hansi-font-family: FrutigerLTStd-Light;">-</span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">1.30)</span></b><b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"></span></b></span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
</td>
</tr>
<tr style="mso-yfti-irow: 2;">
<td rowspan="2" style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">KONTRAKO ERAGINAK</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">UGALTZE APARATUKO INFEKZIOAK EMAKUMEETAN</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">4,81(2,51-9,24)</span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">17(8-41)</span><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"></span></span></div>
</td>
</tr>
<tr style="mso-yfti-irow: 3;">
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"><span style="mso-spacerun: yes;"> </span>UGALTZE
APARATUKO INFEKZIOAK GIZONETAN</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">3,98(2,6-6,1)</span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">32(19-59).</span><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"></span></span></div>
</td>
</tr>
<tr style="mso-yfti-irow: 4;">
<td rowspan="4" style="border-top: none; border: solid windowtext 1.0pt; mso-border-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">BIGARREN MAILAKO PREBENTZIO TALDEA</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">ALDAGAI KONBINATUA</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><br /></span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">0.82 (0.72</span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-GB" style="font-family: GandhariUnicode-Roman; mso-ansi-language: EN-GB; mso-bidi-font-family: GandhariUnicode-Roman; mso-hansi-font-family: FrutigerLTStd-Light;">-</span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">0.95)</span></b><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"></span></span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">137 (88-494)</span></b><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"></span></span></div>
</td>
</tr>
<tr style="mso-yfti-irow: 5;">
<td rowspan="3" style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">KONTRAKO ERAGINAK</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">UGALTZE APARATUKO INFEKZIOAK EMAKUMEETAN</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">3,98(2,12-7,48)</span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">17(8-45)</span><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"></span></span></div>
</td>
</tr>
<tr style="mso-yfti-irow: 6;">
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">UGALTZE APARATUKO INFEKZIOAK GIZONETAN</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">3,68(2,72-4,98)</span></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">36(24-56)</span><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"></span></span></div>
</td>
</tr>
<tr style="mso-yfti-irow: 7; mso-yfti-lastrow: yes;">
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">HANKEN MOZKETA</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">2,07(1,43-3)</span></b></div>
</td>
<td style="border-bottom: solid windowtext 1.0pt; border-left: none; border-right: solid windowtext 1.0pt; border-top: none; mso-border-alt: solid windowtext .5pt; mso-border-left-alt: solid windowtext .5pt; mso-border-top-alt: solid windowtext .5pt; padding: 0cm 5.4pt 0cm 5.4pt;" valign="top"><div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-GB" style="font-family: FrutigerLTStd-Light; mso-ansi-language: EN-GB; mso-bidi-font-family: FrutigerLTStd-Light;">22(12-55)</span></b><span lang="EU" style="font-family: "arial"; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";"></span></span></div>
</td>
</tr>
</tbody></table>
<div class="Preformatted" style="margin-bottom: 5.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 5.0pt; tab-stops: 35.4pt;">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">Iruzkinak:</span></b></div>
<div class="MsoNormal" style="text-indent: 36.0pt;">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><span lang="EU">Ausazko saiakuntza kliniko bat da.Sekuentzia ongi ezkutatzen dute.Itsu
bikoitza da (ikerlariak eta gaixoak). Botikak itxura berdina daukate.Jadad
eskalan 5 puntu ditu.Emaitzak arriskuko Cox ereduarekin aztertzen dituzte.</span><span lang="EU">Ez dago heterogeneotasunik.</span></span></div>
<div class="MsoNormal" style="text-indent: 36.0pt;">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small;">Bigarren mailako prebentzioan, nahiz eta aldagai
konbinatuan emaitza esanguratsua izan, ez da esanguratsua osagaietan, bihotzeko
infartuan izan ezik eta oso alde txikiagatik (0,63-0,99).</span></div>
<div class="MsoNormal">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small;"><span style="mso-tab-count: 1;"> </span>Emaitza hauekin ezin daiteke
gomendatu Kanagliflozina 2 motako diabetikoetan bihotz-hodietako gaixotasuna
ekiditeko,onurak txikiak baitira,kontrako eraginak larriak eta sarriak dira eta
salneurria altua da.</span></div>
<div class="MsoNormal">
<span style="font-family: "verdana" , sans-serif; font-size: x-small;"><b style="mso-bidi-font-weight: normal;"><span lang="EU">Aztertzailea</span></b><span lang="EU"> : Mikel Moreno.</span></span></div>
<div class="MsoNormal">
<b style="mso-bidi-font-weight: normal;"><span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small;">Laguntzaileak: MBE-Osatzen taldea.</span></b></div>
<div class="H5" style="mso-outline-level: body-text; page-break-after: auto;">
<span lang="EU" style="font-family: "verdana" , sans-serif; font-size: x-small; mso-ansi-language: EU; mso-bidi-font-family: "Times New Roman";">Data: 2018-04-09</span></div>
<br />
<br />
<!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" LatentStyleCount="156">
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Tabla normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman";
mso-ansi-language:#0400;
mso-fareast-language:#0400;
mso-bidi-language:#0400;}
</style>
<![endif]--><br />
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-38683333023166146122018-04-03T15:03:00.000+02:002018-04-04T08:25:44.646+02:00LEHEN ARRETA MAILAren gorabeherak eta hausnarketak <table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhojkR18iS9IAdLLrSboRBJKl0tf21FrUisR1tEZseD0JUQmOaOM9D5xOcusKehdvdF3oip4GbX-kldWmqlSQ86fdHBEp1jbD48bsSYDaQ1sKElbsjHTlkZRaNlaMndhdqBs2lNtWR9DN8/s1600/vstrecha2.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="360" data-original-width="480" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhojkR18iS9IAdLLrSboRBJKl0tf21FrUisR1tEZseD0JUQmOaOM9D5xOcusKehdvdF3oip4GbX-kldWmqlSQ86fdHBEp1jbD48bsSYDaQ1sKElbsjHTlkZRaNlaMndhdqBs2lNtWR9DN8/s320/vstrecha2.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: "verdana" , sans-serif;"><a href="https://zakrevskogo42a.info/4-sektsiya/7-10-16-v-17-00-vstrecha-investorov-4-sektsii-s-glavoy-osbb-ruslanom/" target="_blank">Marrazkia hemengoa da </a></span></td></tr>
</tbody></table>
<span style="font-family: "verdana" , sans-serif;">Duela hilabete batzuk Lehen Arreta Arnasberritzen (LAA) mugimendua sortu zen osasungintzako maila honetan aspaldi honetan bizi ditugun gorabeherei irtenbide bat bilatzeko asmoarekin. Hori dela eta, hausnarketa txosten hau sortu genuene. (<a href="https://drive.google.com/file/d/1dgjW5Y0vkrZoPz5RBzWHAwn3jC-vjce8/view?usp=sharing" target="_blank">euskeraz</a>; <a href="https://drive.google.com/file/d/19VnzBRMxo8FuYrIOe1qG0yEW_JLm5-g6/view?usp=sharing" target="_blank">gaztelaniaz</a>)</span><br />
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;">Gure arteko eta Administrazioarekin izan ditugu bilerak eta pixkanaka, lehen arreta maila hobetzeko bidean aurrera goazela sinetsi nahi dugu.</span><br />
<span style="font-family: "verdana" , sans-serif;"><br />Oraingo honetan, hemen jartzen dizuet Osakidetza et Osasun sailak sortutako eta gure artean eztabaidatzeko bidali digun txostena. (<a href="https://drive.google.com/file/d/1qRT_VKghSuSiWCZAGikl1taWhJvHB5X6/view?usp=sharing" target="_blank">euskeraz</a>; <a href="https://drive.google.com/file/d/1HpdLG242jRvls9zh0d7Qk9CqVqyT6pSm/view?usp=sharing" target="_blank">gaztelaniaz</a>)</span><br />
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;">Hitza eman digutenez, oso garrantzizkoa jotzen dugu elkarhizketetan parte hartzea . Iritzi propioaz gain, bi txostenen arteko ezberdintasunak aztertzera gonbidatzen zaitugu. </span>Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-84568552371628918402018-02-27T23:11:00.002+01:002018-02-27T23:11:55.112+01:00BRONKIEKTASIEN INGURUKO GALDERAK <br />
<br />
<i><span style="font-family: Verdana, sans-serif;"> KASUA : Duela 2 hilabete kontsultara etorri zen 86 urteko eta bronkiektasiak dituen gizonezko bat, esanez, bazeramala bizpahiru egun karkaxa pittin bat ugaritzen ari zitzaiola . Ez zeukan arnasesturik, ezta sukarrik eta karkaxa zuria </span></i><br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi0lGGw_xMqnU94tlz4bOqy-gqttkig329YhcbXDoX2Vbg-EDskT047odRMp48gyky8tQy3jByRX47p7LoylZt2lMd3nHjyDDpN3x3oM3h9AbVTHVpWvEwC2Hc1XE7Kw_BFOauUpRK0SWI/s1600/pulmon+8.jpg" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="272" data-original-width="296" height="183" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi0lGGw_xMqnU94tlz4bOqy-gqttkig329YhcbXDoX2Vbg-EDskT047odRMp48gyky8tQy3jByRX47p7LoylZt2lMd3nHjyDDpN3x3oM3h9AbVTHVpWvEwC2Hc1XE7Kw_BFOauUpRK0SWI/s200/pulmon+8.jpg" width="200" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="http://patob2014uezen.blogspot.com.es/2014/08/bronquiectasias.html" target="_blank"><span style="font-family: Verdana, sans-serif;">Marrazkia hemendik lortu dugu </span></a></td></tr>
</tbody></table>
<i><span style="font-family: Verdana, sans-serif;">zen. Itxurak, explorazioak eta konstanteek egoera larri baten aurrean ez geundela adierazten zutenez, karkaxaren kultiboa eskatu nuen. </span></i><br />
<i><span style="font-family: Verdana, sans-serif;">Kultiboa negatiboa izan zen eta emaitza jasotzera etorri zenean, hobeto zegoela eta ohikoa den karkaxa kantitatera itzulita zegoela adierazi zidan. Guztia kontutan hartuta ez nion tratamendu berririk jarri.</span></i><br />
<i><span style="font-family: Verdana, sans-serif;">Neumologak hau jakin zuenean, desadostasuna azaldu zuen eta Amoxizilina -klabulaniko 8 orduro hartu arazi zion 15 egunetan. </span></i><br />
<span style="font-family: Verdana, sans-serif;">Zuek nola jokatuko zenuteke kasu honetan?</span><br />
<br />
<span style="font-family: Verdana, sans-serif;">Kasu honen aurrean funtsezko 2 galdera sortu zitzaizkigun Osatzeneko EOO_MBE taldean. </span><br />
<span style="font-family: Verdana, sans-serif;">1.- Nola antzeman edo definitu bronkiektasien gaizkitze akutua? </span><br />
<span style="font-family: Verdana, sans-serif;">2.- gaizkitze akutu baten aurrean gaudela onartuz, zein eta zein iraupeneko </span><span style="font-family: Verdana, sans-serif;">tratamenda da egokiena? </span><br />
<span style="font-family: Verdana, sans-serif;"> 1.ari erantzuteko ikerketa transbertsalak edota entsegu klinikoak eta 2.ari erantzuteko entsegu klinikoak beharko genituzke baina </span><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;">bilaketa zabala egin ondoren, <b>ez dugu ikerketa sendorik topatu</b>. Ondorioz, <b>erantzunak adituen adostasunaren bidez erabakitakoak direnez, oso posible da etorkizunean estudio berriek kontrakoa adieraztea .</b></span></span><br />
<br />
<span style="color: blue;"><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;">Gaizkitze akutuaren diagnosia, pazienteak aipatzen dituen sintomen baturak eta artatzen ari den klinikoaren iritziak </span></span><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;">eraikitzen du</span></span>. Antibiotikoa ematea erabakitzearren, espektro zabaleko amoxizilina /klabulanikoa dosi altuetan aukeratzen da eta gehienetan 10-14 egunetan hartzea gomendatzen da.</span></span></span><br />
<span style="color: blue;"><span style="color: black;"><span style="font-family: Verdana, sans-serif;"><span style="font-family: Verdana, sans-serif;">Erantzunaren xehetasunak ezagutu nahiez gero, sakatu <a href="http://osatzenmbe2.blogspot.com.es/" target="_blank">hemen </a> </span></span></span></span>Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-47074690107833708592018-02-21T15:38:00.000+01:002018-02-21T15:38:04.882+01:00D BITAMINERIK BEHIN ETA BERRIRO BUELTAKA<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZCF1vGOUDB67FESoh5otznB4a_4WPzXhTpd6FN56-AlSos0yjmbZ6BBTPi0VTFDnflWQwe9vX5SHXi4VIWOv6uE4HD1iIdwNPtTgNL5yjLwdeckAKCHJ10ktyOwNqonDH1BqUsAbr3Lg/s1600/vitamina-D.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="500" data-original-width="500" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjZCF1vGOUDB67FESoh5otznB4a_4WPzXhTpd6FN56-AlSos0yjmbZ6BBTPi0VTFDnflWQwe9vX5SHXi4VIWOv6uE4HD1iIdwNPtTgNL5yjLwdeckAKCHJ10ktyOwNqonDH1BqUsAbr3Lg/s320/vitamina-D.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: Verdana, sans-serif;"><a href="http://fmdiabetes.org/vitamina-d-crecimiento/" target="_blank">Irudia hemengoa da </a></span></td></tr>
</tbody></table>
<br />
<br />
<span style="font-family: Verdana, sans-serif;">2010ean gai honi buruz <a href="http://tolosakoosasunzentroa.blogspot.com.es/2010/12/d-bitamina-modan-jarri-da.html" target="_blank">sarrera hau</a> egin genuen ; bertan, D bitamina modan jartzen ari zela azaldu genuen eta balore normalen tarteetan aldakortasun handia zegoenez, itxarotea gomendatu genuen .</span><br />
<span style="font-family: Verdana, sans-serif;"> Ikusten denez, D Bitamineren maila ezagutzeko laborategirako eskaerak goruntz doaz etengabe. </span><br />
<span style="font-family: Verdana, sans-serif;">Rafa Bravok bere blogean egindako <a href="https://rafabravo.blog/2018/02/18/es-hora-de-que-los-medicos-y-pacientes-frenemos-nuestro-entusiasmo-por-la-deteccion-y-la-administracion-de-suplementos-de-vitamina-d/" target="_blank">sarrerak</a> informazio ona dakar gai honekin lotuta.</span><br />
<span style="font-family: Verdana, sans-serif;">Berak dio denok, mediku eta pazienteek, D Bitamenarekiko gogo handi hori baretzen utzi behar dugula Nere ustez, pazienteek ez lukete eskatuko ez bagenu gu geok , farmazia-industriak eta komunikabideek azaleratu .</span><br />
<br />Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-57530204793145730072018-01-18T22:13:00.000+01:002018-01-18T22:13:05.482+01:00GRIPEA ETORRI DELA ETA??? <div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjoXN5Z3SMkwOyBvIUkZFP8z0Y8bnvbj52ZYost8d5atbZMnsw_mraxMjnSdvoXEOFagQh1RZv5yU3-oy6F6At-B_NDUGuLYq7j6L4BIrMxgMRyuf4eeXmXiULjqBMZZ0_Jno5IPZFSE3Q/s1600/images.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="307" data-original-width="164" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjoXN5Z3SMkwOyBvIUkZFP8z0Y8bnvbj52ZYost8d5atbZMnsw_mraxMjnSdvoXEOFagQh1RZv5yU3-oy6F6At-B_NDUGuLYq7j6L4BIrMxgMRyuf4eeXmXiULjqBMZZ0_Jno5IPZFSE3Q/s1600/images.jpg" /></a></div>
<br />
<br />
<span style="font-size: large;">Merezi du <a href="http://atencioncontinuada.blogspot.com.es/" target="_blank">blog honetan</a> esaten dutena irakurtzea </span><br />
<br />
<span style="font-size: large;">Ezin da hobeto eta argiago esan </span><br />
<br />
<span style="font-size: large;">Beldurra sartzeak ez du ezer laguntzen </span><br />
<span style="font-size: large;"> </span><br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiqsPvWNVt8tdj1o0bqd4jaUzWYf8lypW3QCkpZ6msNl8s-BYaGdsp3ugKy1XJyrkIIg5LbGk-HeX1mlfMKNilHYFSYshreIHKsvZWYk3V98Qr4smqmsQTcqbjjx5cMaSPCrAwSNMsCg9g/s1600/man-with-flu-cartoon-coloring-page-image_csp22803177.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="470" data-original-width="238" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiqsPvWNVt8tdj1o0bqd4jaUzWYf8lypW3QCkpZ6msNl8s-BYaGdsp3ugKy1XJyrkIIg5LbGk-HeX1mlfMKNilHYFSYshreIHKsvZWYk3V98Qr4smqmsQTcqbjjx5cMaSPCrAwSNMsCg9g/s320/man-with-flu-cartoon-coloring-page-image_csp22803177.jpg" width="162" /></a></div>
Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-47730272277023223272017-11-27T14:40:00.001+01:002017-11-27T14:40:22.253+01:00LEHEN ARRETA ARNASBERRITZEN mugimendua <span style="font-family: Georgia, serif; font-size: 10pt;"><b><span style="color: #000099; text-decoration-line: none;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgag8bwQN6kCOpXsOd8yI6sUWm5_PYoY6HTZlHN_9NiJ-ouPOM51d_PrwLt1URIYaAJj0LHay45cCo_euCUrc4Dl1ASPufO1bqhl8SWCLmzsE-gS-FR3e531roX2qTYS6HxM7bTNKfVj_Y-/s1600/Captura+de+pantalla+de+2017-11-08+18%253A28%253A23.png"><img border="0" data-original-height="502" data-original-width="571" height="175" id="_x0000_i1025" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgag8bwQN6kCOpXsOd8yI6sUWm5_PYoY6HTZlHN_9NiJ-ouPOM51d_PrwLt1URIYaAJj0LHay45cCo_euCUrc4Dl1ASPufO1bqhl8SWCLmzsE-gS-FR3e531roX2qTYS6HxM7bTNKfVj_Y-/s200/Captura+de+pantalla+de+2017-11-08+18%253A28%253A23.png" width="200" /></a> </span></b></span><br />
<span style="font-family: Georgia, serif; font-size: 10pt;"><span style="text-decoration-line: none;"><br /></span></span>
<span style="font-family: Georgia, serif; font-size: 10pt;"><span style="text-decoration-line: none;">Lehen arreta mailan antzematen da kezkak daudela eta honen inguruan, talde batek honako <a href="https://drive.google.com/file/d/0B1vpaOkvgp4wdDdEcXhGQW9rSms/view" target="_blank">txosten hau</a> sortu du .</span></span><br />
<span style="font-family: Georgia, serif; font-size: 10pt;"><span style="text-decoration-line: none;"><br /></span></span>
<span style="font-family: Georgia, serif; font-size: 10pt;"><span style="text-decoration-line: none;"> Irakurri ondoren ados bazaude jartzen duenarekin , eskertuko genuke zure oniritzia ematea <a href="https://docs.google.com/forms/d/e/1FAIpQLSeyoC7S1jYMYumtwcOx2MlgaNWGVkVrCsDgkH3uRJiYmpEGig/viewform" target="_blank">hemen </a> </span></span><br />
<span style="font-family: Georgia, serif; font-size: 10pt;"><b><span style="color: #000099; text-decoration-line: none;"><br /></span></b></span>Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-77425674805488119362017-09-26T21:06:00.000+02:002017-09-26T21:06:47.202+02:00ESKERRAK DENOI<span style="font-family: Verdana,sans-serif;"><br /></span>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhksbTxVcxLnPIxDKxdrP8ChTxGVO5IihViXWMHaVvhQzG23lbe2yCxWHibQZ9DaElgz8UZotW9caD7elEIucgMvGXffVf05fV99TqTChk7GCHwProHrhyzKlCXdSlYeWyHVHfx2l3AjEc/s1600/munduko-txokoa-eskerrikasko-20001.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="1600" data-original-width="1495" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhksbTxVcxLnPIxDKxdrP8ChTxGVO5IihViXWMHaVvhQzG23lbe2yCxWHibQZ9DaElgz8UZotW9caD7elEIucgMvGXffVf05fV99TqTChk7GCHwProHrhyzKlCXdSlYeWyHVHfx2l3AjEc/s320/munduko-txokoa-eskerrikasko-20001.jpg" width="299" /></a></div>
<br /><span style="font-family: Verdana,sans-serif;"><span style="font-family: Verdana,sans-serif;">Kaixo lankideak eta besteak .</span></span><br />
<span style="font-family: Verdana,sans-serif;">Argitaratu dudan gutunean azaltzen den galderari, dagoeneko 1644 lagunek erantzun dute eta hauetatik %99.5ek kontakizuna partekatzen dutela diote .</span><br />
<span style="font-family: Verdana,sans-serif;"><br /></span>
<span style="font-family: Verdana,sans-serif;">Hasteko eskerrak eman nahi dizkizuet izenpetu duzuen guztioi.</span><br />
<br />
<span style="font-family: Verdana,sans-serif;">Jakingo duzuen bezela, sare sozial, egunkari eta irratietara zabaldu da,</span><span style="font-family: Verdana,sans-serif;"><span style="font-family: Verdana,sans-serif;"> hasiera batean medikuen artean soilik zabaltzea nere asmoa</span> </span><span style="font-family: Verdana,sans-serif;"><span style="font-family: Verdana,sans-serif;">bazen ere</span></span><span style="font-family: Verdana,sans-serif;">. </span><br />
<span style="font-family: Verdana,sans-serif;">Gutunak egin duen bidea ez da nere erabakia izan. Momentu askotan gaindituta sentitu naiz baina jaso ditudan elkartasun mezu pilak asko lagundu naute.</span><br />
<br />
<span style="font-family: Verdana,sans-serif;">Elkarhizketa bat baina gehiago eskatu dizkidate komunikabideetatik eta guztiei berdina esan diet : Idatzitakoa adibide bat besterik ez da eta hor adierazten den arazoa ez da pertsonala baizik eta </span><span style="font-family: Verdana,sans-serif;">orokorrean </span><span style="font-family: Verdana,sans-serif;">lehen arreta mailakoa. </span><br />
<span style="font-family: Verdana,sans-serif;">Aspaldi antzeman dugu norabide ezean gabiltzala eta lehen mailako narriadura areagotzen ari dela.</span><br />
<span style="font-family: Verdana,sans-serif;">Denok gara honen erantzule eta denok dugu zeregina, politikoen apustu berezitik hasita profesionalen eginbeharretaraino. </span><br />
<span style="font-family: Verdana,sans-serif;"><span style="font-size: large;"><b>Borondatea eta hitzegitea da behar dena</b></span> </span><br />
<span style="font-family: Verdana,sans-serif;"> </span>Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-73772522477048708692017-09-10T18:40:00.000+02:002017-09-10T18:40:06.016+02:00GAINEZKA LEHEN ARRETAN : KONPONDU BEHARKO DUGU EZ?<span style="font-family: "verdana" , sans-serif;">Aspaldi honetan , lanak eta zentzugabekeriak gora egin dute lehen arretan eta ez dugu astirik taldean elkartu eta, </span><span style="font-family: "verdana" , sans-serif;">bilaketa bibliografiko eta artikuluen azterketa kritiko bidez </span><span style="font-family: "verdana" , sans-serif;">gure galdera klinikoei erantzuna emateko. </span><br />
<br />
<span style="font-family: "verdana" , sans-serif;">Duela gutxi , lan egun gogor horietako baten ondoren gainezka egin nuen eta idatzi bat sortu nuen. Zoritxarrez, ohikoa eta orokortuegia bihurtzen ari den egoera dela uste dut. Nahi eta nahi ez, konponbidea bilatzeko unea iritsi da! </span><br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhH8Q9uFtr5CEpJXT1o-kO0MMMRdo7MBTxY8Tjz7uT-ahaHTro9ehTi98xXW1fDynDL8yXliTzzcrOr_lT2REN-i_dkmTzHchohTeuuYj-oH_BeKhRbe82-ULu7WsN1y-ZmjGdKhzgzXK0/s1600/Stress-The-No-1-Reason-Why-Your-Not-Losing-Weight.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="995" data-original-width="1600" height="198" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhH8Q9uFtr5CEpJXT1o-kO0MMMRdo7MBTxY8Tjz7uT-ahaHTro9ehTi98xXW1fDynDL8yXliTzzcrOr_lT2REN-i_dkmTzHchohTeuuYj-oH_BeKhRbe82-ULu7WsN1y-ZmjGdKhzgzXK0/s320/Stress-The-No-1-Reason-Why-Your-Not-Losing-Weight.jpg" width="320" /></a></div>
<span style="font-family: "verdana" , sans-serif;">Gutunaren bukaeran, adierazten dena partekatzen duzun edo ez esateko aukera daukazu</span><br />
<br />
<b><span style="color: blue;"><span style="font-size: x-small;"><i><span style="font-family: "verdana" , sans-serif;"> GAINDITUTA SENTITZEN DEN MEDIKU BATEN GUTUNA</span></i></span></span></b><br />
<br />
<b><span style="font-family: "verdana" , sans-serif;"><span style="color: blue;"><span style="font-size: x-small;"><i> Ina Idarreta, lehen mailako arretako familia medikua naiz,duela 35 urtez geroztik eta azken 27ak leku berean eman ditut goizeko 8etatik arratsaldeko 3etara bitarteko ordutegian. Kontakizun hau nire antzeko lana egiten duen edonork berdin-berdin idatz zezakeen, edozein dela bere adina, eskarmentua, lanlekua edo kontratu mota.<br />Nere asmoa da, atxikidurak jasotzea eta dagokionak benetan jakin dezan ez dela arazo partikular bat edo egun bateko kontua; izan ere, profesional askok dugu arazo berbera eta arazo honek errespetua, aintzat hartua izatea eta konponketa eskatzen du....</i></span></span></span></b><br />
<br />
<span style="font-family: "verdana" , sans-serif;"><a data-saferedirecturl="https://www.google.com/url?hl=es&q=https://docs.google.com/forms/d/e/1FAIpQLSeDiN98mqITJJZiQ5JAURNUTjgAVaLwJKrkzes888Qeee4edA/viewform?usp%3Dsf_link&source=gmail&ust=1505145604574000&usg=AFQjCNEDrL3WQBmHMnYwHy9RcxpiyXlySg" href="https://docs.google.com/forms/d/e/1FAIpQLSeDiN98mqITJJZiQ5JAURNUTjgAVaLwJKrkzes888Qeee4edA/viewform?usp=sf_link" target="_blank">Gutun osoa-galdetegia Euskeraz</a></span><br />
<br />
<br />
<span style="font-family: "verdana" , sans-serif;"></span><br />
<span style="font-family: "verdana" , sans-serif;"><a data-saferedirecturl="https://www.google.com/url?hl=es&q=https://docs.google.com/forms/d/e/1FAIpQLSf2IfJ-5IvWx_Qk_ArTWKNsQRru7-nL5pDNtsBPH53xd-exMw/viewform?usp%3Dsf_link&source=gmail&ust=1505145604574000&usg=AFQjCNEcemRgY6MRzLfO5wL0S2b6mdk5Iw" href="https://docs.google.com/forms/d/e/1FAIpQLSf2IfJ-5IvWx_Qk_ArTWKNsQRru7-nL5pDNtsBPH53xd-exMw/viewform?usp=sf_link" target="_blank">Carta-Cuestinario Castellano </a></span>Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-35098497942528884532017-09-04T08:53:00.000+02:002017-09-04T08:53:09.964+02:002017ko ABUZTUA<ol>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28639846?dopt=Abstract" target="_blank">Hortzetako prozeduretan ez da beharrezkoa antibiotikorik ematea hezur-giltzaduretako protesien infekzioa ekiditeko.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28642330?dopt=Abstract&otool=icamculib" target="_blank">Giltzurruneko gutxiegitasun kronikoan ez da beharrezkoa tentsio sistolikoa 120tik jaistea.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28787537?dopt=Abstract" target="_blank">Hipertentsioa daukaten adintsuetan tentsioaren kontrol zorrotzak ez dakar onurarik.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28829876" target="_blank">Bihotzeko gutxiegitasuneko tratamendua ( </a><span class="spanHizkunAukeratua" id="spanHizkunAukeratua"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28829876" target="_blank">eiekzio-frakzio murriztuarekin) berdina da BNP kontutan izanik ala ez.</a></span></li>
</ol>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-84954469592701221612017-08-23T13:01:00.000+02:002017-08-23T13:01:00.806+02:00MINFULLNESSeko saio motzaren eraginkortasuna Osasungintzan <table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiNCXk7UQs1GijA_PGflCLks3LYm-VotYD2XeGC_NJQZB1nal9HwNlEYc7k9wVOdoVSYGHMasHv72gApxt-6tXTEvPR3ww1q76LnlR06YysJGZ6mbqmZoKorJ5QRO1_yh7hDqCo8uwBfPg/s1600/mindfullness2.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="179" data-original-width="429" height="133" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiNCXk7UQs1GijA_PGflCLks3LYm-VotYD2XeGC_NJQZB1nal9HwNlEYc7k9wVOdoVSYGHMasHv72gApxt-6tXTEvPR3ww1q76LnlR06YysJGZ6mbqmZoKorJ5QRO1_yh7hDqCo8uwBfPg/s320/mindfullness2.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: "verdana" , sans-serif;"><a href="http://heronlinenetwork.com/2017/03/17/modern-meditation-practices-balanced-life/" target="_blank">Marrazkia hemendik lortu dugu</a></span><br />
<br />
<div style="text-align: left;">
<span style="color: blue; font-family: verdana, sans-serif; font-size: 12.8px;">MINDFULNESSen definizioa wikipedian agertzen den moduan honako hau da :</span></div>
</td></tr>
</tbody></table>
<div style="background-color: white; font-family: sans-serif; font-size: 14px; line-height: inherit; margin-bottom: 0.5em; margin-top: 0.5em;">
<i><span style="color: blue;">El mindfulness moderno está basado en la meditación <a href="https://es.wikipedia.org/wiki/Vipassana" style="background: none; text-decoration-line: none;" title="Vipassana">Vipassana</a>, una antigua técnica de meditación de la India que consiste en "tomar conciencia del momento presente", "tomar conciencia de la realidad".</span></i></div>
<div style="background-color: white; font-family: sans-serif; font-size: 14px; line-height: inherit; margin-bottom: 0.5em; margin-top: 0.5em;">
<i><span style="color: blue;">Consiste en prestar atención, momento a momento, a pensamientos, emociones, sensaciones corporales y al ambiente circundante, aceptándolos, es decir, sin juzgar si son correctos o no. La atención se enfoca en lo que se percibe, sin dar pie a rumiación, definida esta última como la preocupación excesiva por los problemas y sus posibles causas y consecuencias, en vez de estar dirigida a buscar soluciones.</span></i></div>
<div style="background-color: white; font-size: 14px; line-height: inherit; margin-bottom: 0.5em; margin-top: 0.5em;">
<span style="font-family: "verdana" , sans-serif;"> <span style="color: blue;">Bideo honetan<a href="https://es.wikipedia.org/wiki/Jon_Kabat-Zinn" target="_blank"> Kabat_Zinn J </a>adituak ederki azaltzen du (azpitituluak euskeraz edo gaztelaniaz jarri daitezke)</span></span><br />
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<div class="separator" style="clear: both; text-align: center;">
<iframe width="320" height="266" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/ybgH4WQH9_k/0.jpg" src="https://www.youtube.com/embed/ybgH4WQH9_k?feature=player_embedded" frameborder="0" allowfullscreen></iframe></div>
<span style="font-family: "verdana" , sans-serif;">Alerta bibliografiko batean artikulua hau topatu dut eta hemen azalduko dut egin dudan irakurketa kritikoa</span><span style="font-family: sans-serif;"> </span></div>
<span style="font-family: "verdana" , sans-serif;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28687263?dopt=Abstract&otool=icamculib" target="_blank"><span style="font-size: x-small;"><span style="color: #660066;"><span style="background-color: white; border-bottom-color: initial; border-bottom-style: initial; outline-color: initial; outline-style: initial;">Gilmartin H</span></span>,2017, <span style="background-color: white;">Brief Mindfulness Practices for Healthcare Providers - A Systematic Literature Review</span></span><span style="background-color: white; font-size: 1.4em;">.</span></a></span><span style="font-family: Verdana, sans-serif; font-size: x-small;">Osasungintzan praktikara eramateko oztoporik handienetako bat denboraren beharra denez, azterketa sistematiko honek saio motzen eraginkortasunaren ikuspuntutik abiatu da</span><br />
<span style="font-family: Verdana, sans-serif; font-size: x-small;"><br /></span>
<br />
<ul>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;">Bilaketaren azken eguneraketa 2017ko ekainaren 24ean egin dute.</span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;">Mota ezberdinetako ikerketak hartu dituzte kontuan(entseguak, kualitatiboak,..) </span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;">stressa pairatu dezaketen populazioan oinarritu dira.</span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;">4 ordutik beherako parte-hartzeak aztertu dira: meditazioa,erlajazioa, yoga etabarreko jarduerak. 5-20minutuko eguneroko saioak edo 30'astean behin.Bataz bestekoa astean bitan. %65ek 8 asteko etxeko saioak ere, CD grabazio bidez. <i>Aldakortasun handia antzeman dute.</i> </span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;"><i>Saioekiko atxikudura estuio batek bakarrik aztertu du.</i></span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;">ongizatea (norberak antzematen duena )eta ibileraren(testak, notak,..) neurketa izan dira emaitzarik garrantzizkoenak .</span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;">3 ikertzaile eta beraien adostasun-ezadostasuna Kappa indize bidez aztertu dute .Alborapen arriskua ere aztertu dute :</span> <i>ikerketa kuantitaboen kalitatea erdi mailakoa dela eta kualitatiboenena baxua antzeman dute </i>. <span style="font-family: Verdana, sans-serif; font-size: x-small;">Heterogeneotasuna ez dute aztertu.</span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;">14 estudio guztira. Tamaina 10-245ko tartekoa ;%78 emakumezkoak. gehinetan mindfulness saioa erizainak edo erizain ikasleak gidatutakoa. </span><span style="font-family: Verdana, sans-serif; font-size: x-small;">Kappa 0.91.Laburpena narrazio moduan egin dute .</span></li>
<li><span style="font-family: Verdana, sans-serif; font-size: x-small;">Metodologikoki ondo egina da azterketa sistematikoa </span></li>
</ul>
<span style="font-family: Verdana, sans-serif; font-size: x-small;"><b>EMAITZAK</b></span><br />
<br />
<span style="font-family: Verdana, sans-serif; font-size: x-small;"><b>Ongizatea : </b>gehienetan hobekuntza esanguratsua antzeman da stress edo antsietate mailan.</span><br />
<span style="font-family: Verdana, sans-serif; font-size: x-small;"><b>Ibilbidea: </b>2 ikerketek soi</span><span style="font-family: Verdana, sans-serif; font-size: x-small;">lik aztertu dute . Minfulnessek ez du antsietatea , depresioa edo memoria hobetu.</span><br />
<span style="font-family: Verdana, sans-serif; font-size: x-small;"><br /></span>
<span style="font-family: Verdana, sans-serif; font-size: x-small;"><b>ONDORIOAK </b></span><br />
<span style="font-size: x-small;"><span style="font-family: Verdana, sans-serif;">Metodologikoki ondo egina dagoen azterketa sistematiko honen arabera Mindfulnesseko saio motzak eraginkorrak izan daitezke stressa eta antsietatea gutxitzen baina estudioen kalitate eskasak eta tratamenduen aldakortasunak gomendio sendoa ematea oztopatzen dute.</span></span><br />
<span style="font-size: x-small;"><span style="font-family: Verdana, sans-serif;"> Ikerketa batzuk proposatzen dute jarduerak lehen mailan egiteko irisgarriak direla uste dugu(ikusi 1taula) eta </span></span><span style="font-family: Verdana, sans-serif; font-size: x-small;">ikerketarako bide interesgarria dela ere.</span><br />
<br />
<br />Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-57043012824868145002017-08-15T21:11:00.000+02:002017-08-23T08:55:57.464+02:00Eiekzio-frakzio normala duen bihotzeko ezintasunaren tratamendua <div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgEZ0dLUWYLbY3B0xD55pTqbRUxUvycMM5QmCFUBPpQl0ERWO-0MreSiAHKyeadqooQcdUqukcB6ZFcf1W0TQr6rk4TS_p3OVVUOacob-jD4NWAJ0H1U7LKbkHze7DKrn1bYOHvZVziJF0/s1600/corazon--575x390.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="390" data-original-width="575" height="217" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgEZ0dLUWYLbY3B0xD55pTqbRUxUvycMM5QmCFUBPpQl0ERWO-0MreSiAHKyeadqooQcdUqukcB6ZFcf1W0TQr6rk4TS_p3OVVUOacob-jD4NWAJ0H1U7LKbkHze7DKrn1bYOHvZVziJF0/s320/corazon--575x390.jpg" width="320" /></a><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Aproximadamente un 40-50% de los pacientes con insuficiencia cardiaca presenta una fracción de eyección normal. Hoy día se asume que la disfunción diastólica es la causa del cuadro, pero persiste cierto grado de controversia derivado de la dificultad que entraña su valoración ecocardiográfica y de una elevada tasa de errores diagnósticos. .. <a href="http://www.revespcardiol.org/es/concepto-pronostico-insuficiencia-cardiaca-con/articulo/13091621/" target="_blank">gehiago irakurri ...</a></span></span><br />
<span style="font-family: "verdana" , sans-serif;"></span><br />
<span style="font-family: "verdana" , sans-serif;"></span><br />
<span style="font-family: "verdana" , sans-serif;"></span><br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; clear: right; float: right; font-size: 12.8px; margin-bottom: 1em; margin-left: 1em;"></span></span><br />
<a href="https://www.uptodate.com/es/home" target="_blank"><span style="font-family: "verdana" , sans-serif;"><br /></span></a>
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><a href="https://www.uptodate.com/es/home" target="_blank">Up To date</a>-n diagnostiko bereizle taula interesgarria dator </span></span><br />
<br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Orain arte ezer gutxi dakigu kasu hauen pronostikoa alda dezaken tratamenduetaz.</span></span><br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Hori dela eta, <a href="https://www.blogger.com/"></a><a href="https://www.ncbi.nlm.nih.gov/pubmed?term=2017%5Bpdat%5D+AND+Zheng%5Bfirst+author%5D+AND+drug+heart+failure&TransSchema=title&cmd=detailssearch" target="_blank">Zheng SL-en 2017ko metanalisia<span id="goog_100021783"></span></a> aztertuko dugu oraingo honetan.</span></span><br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Metanalisi honek 25 estudio hartu ditu kontuan ;guztira 18.101 paziente eiekzio-frakzio normala duten bihozteko ezintasunarekin. 2017ko apirila bitarteko bilaketa egin dute.</span></span><br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">3 geruza (estratificación) ezberdinen arabera aztertu dituzte emaitzak. Datuak AEkoak dira (arrisku erlatiboak) </span></span><br />
<br />
<b><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Farmako familiaren arabera </span></span></b><br />
<i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;"> Hilkortasuna </span> </span></span></i><br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"> </span></span><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Beta-blokeatzaileak(BB) </span></span>0.78 (0.65-0.94) </span></span><br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">AEBI (IECA) eta AHB (ARA II) ez esanguratsuak.</span></span><br />
<span style="color: blue;"><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Hilkortasun kardiobaskularra </span></span></i></span><br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">BB 0.75(0.60-0.92)</span></span><br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"> </span></span><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">AEBI (IECA) eta AHB (ARA II) ez esanguratsuak.</span></span><br />
<i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;"> Bihotz ezintasunaren ondorioz ospitaleratzea</span> </span></span></i><br />
<i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">BB ez esanguratsua </span></span></i><br />
<i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">AEBI+AHB 0.90(0.82-0.98) </span></span></i><br />
<br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><b>Jarraipen iraupenaren arabera</b> :</span></span><br />
<span style="color: red;"><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: black;"><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;">Hilkortasuna </span> </span></span></i>3-12hilabete</span> <span style="color: black;">0.79(0.66-0.95)</span></span></span></span><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"> ; >12hilabet Ez esanguratsua</span></span><span style="color: red;"><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"> </span></span></span><br />
<span style="color: red;"><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"> </span></span></span><span style="color: blue;"><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Hilkortasun kardiobaskularra </span></span></i></span><span style="font-family: "verdana" , sans-serif;">3-12 hilabete </span><span style="color: red;"><span style="font-family: "verdana" , sans-serif;"></span></span><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: red;"><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: black;"> 0.71(0.55-0.90);</span></span></span></span>>12hilabet </span></span><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Ez esanguratsua</span></span><span style="color: red;"><span style="font-family: "verdana" , sans-serif;"></span></span><br />
<span style="color: blue;"><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"> </span></span></i></span><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;">Bihotz ezintasunaren ondorioz ospitaleratzea <span style="color: black;">3-12hilabete 0.67(0.48-0.94); >12m 0.90(0.82-0.98)</span></span></span></span></i><i><span style="font-family: "verdana" , sans-serif;"></span></i><br />
<br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><b>Eiekzio-frakzioaren arabera</b> :</span></span><br />
<span style="color: red;"><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: black;"><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;">Hilkortasuna <span style="color: black;">Ez esanguratsua</span></span></span></span></i></span></span></span></span><span style="color: red;"><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: black;"><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;"></span></span></span></i></span></span></span></span><span style="color: red;"><span style="font-family: "verdana" , sans-serif;"></span></span><span style="color: blue;"><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Hilkortasun kardiobaskularra <span style="color: black;">Ez esanguratsua </span></span></span></i></span><i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;"> </span></span></span></i><br />
<i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;">Bihotz ezintasunaren ondorioz ospitaleratzea</span></span></span></i><br />
<i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><span style="color: blue;"> </span></span></span></i><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">> %40-490.88(0.82-0.96) ; >%50 Ez esanguratsua </span></span><br />
<br />
<span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;"><b>EGILEEN ONDORIOAK</b></span></span><br />
<ul>
<li><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">BB-ek erakutsi dute eraginkortasun handiena baina esan beharra dago definizo ezberdinak erabiltzen direla eiekzio-frakzio normal dela esateko (%40 edo 45 edo 50etik gorakoa) eta juxtu BBko estudioek %40tik gorakoa erabili dute.</span></span></li>
<li><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Eiekzio-frakzio normaleko bihotzeko ezintasuna duten pazienteak oso heterogeneoak dira eta komorbilitateak interakzioa izan dezake . Egokiena azpitaldeak bereiztea izango litzake.</span></span></li>
<li><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Paziente hauek orokorrean zaharragoak direnez, bizi kalitatea edo ariketa fisikorako gaitasuna neurtzea hobe izango zen</span></span></li>
<li><span style="font-family: "verdana" , sans-serif;"><span style="background-color: white; font-size: 12.8px;">Mugak: kaltzio-antagonistak, hodi-zabaltzaile edo digoxina ez dira aztertu <b> </b></span></span></li>
</ul>
Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-85996885058518934082017-08-08T12:02:00.000+02:002017-08-08T12:02:10.948+02:00STENT ondorengo antiagregatzaile bikoitza noiz arte? <table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiuzlwOvsPk_0TWP2w3bkFkdxVQhO5s_TkOIugVAYpCLyELe5ydg6FhIwjoOGeD3BNCkav3nH2tBRIXOz2EurpPuUkqfPTmKd3oJBX4PSdvKqEGxcmvbzytbzk76J4SDOg2ZJVdV1lZNGY/s1600/antiagregantes-1.png" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="668" data-original-width="673" height="317" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiuzlwOvsPk_0TWP2w3bkFkdxVQhO5s_TkOIugVAYpCLyELe5ydg6FhIwjoOGeD3BNCkav3nH2tBRIXOz2EurpPuUkqfPTmKd3oJBX4PSdvKqEGxcmvbzytbzk76J4SDOg2ZJVdV1lZNGY/s320/antiagregantes-1.png" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="https://clotosplace.wordpress.com/tag/antiagregantes/" target="_blank">Marrazkia hemendik lortu dugu </a></td></tr>
</tbody></table>
<br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">Orain arte, koronario gertaera akutu baten ondoren STENT-a jartzen zaienei , gehienetan, urtebeterako antiagregatzaile bikoitza hartzea gomendatzen zaie.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;">Azken aldi honetan gero eta ugariagoak dira tratamendu hau luzatzen zaien pertsonak .</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">Honen harira, </span><a href="http://www.amjmed.com/article/S0002-9343(17)30608-3/pdf" style="font-family: Verdana, sans-serif;" target="_blank">Bavishi C 2017</a><span style="font-family: Verdana, sans-serif;">an argitaratu duen metanilisiaren emaitzak hauek dira : </span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<b><span style="font-family: Verdana, sans-serif;">6hilabet vs 12 edo gehiagoko tratamenduen arteko alderaketa </span></b><br />
<b><span style="font-family: Verdana, sans-serif;"><br /></span></b>
<span style="font-family: Verdana, sans-serif;"><i>Kardiobaskular hilkortasuna :%1.9 vs %1.8 (ezberdinatasun ez esanguratsua )</i></span><br />
<span style="font-family: Verdana, sans-serif;"><i>Infartu akutua %2.7 vs %2.5 (ezberdinatasun ez esanguratsua )</i></span><br />
<span style="font-family: Verdana, sans-serif;"><i>Stentaren tronbosia %0.77 vs %0.44 (ezberdinatasun ez esanguratsua )</i></span><br />
<span style="font-family: Verdana, sans-serif;"><i>Garrantzizko odol jarioak %1.1 vs %1.2<b> </b>(ezberdinatasun ez esanguratsua )</i></span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<b><span style="font-family: Verdana, sans-serif;"><br /></span></b>
<b><span style="font-family: Verdana, sans-serif;">12 hilabete vs iraupen luzeagoko tratamenduen alderaketa </span></b><br />
<b><span style="font-family: Verdana, sans-serif;"><br /></span></b>
<span style="font-family: Verdana, sans-serif;"><i>Kardiobaskular hilkortasuna %1.1 vs 0.9%(ezberdinatasun ez esanguratsua )</i></span><br />
<span style="color: blue; font-family: Verdana, sans-serif;"><i>Infartu akutua %3.4 vs % 1.7 AR 2,0 (1.47-2.73) ezberdintasun Esanguratsua </i></span><br />
<span style="font-family: Verdana, sans-serif;"><i>Stentaren tronbosia %1.2 vs %0.5 (ezberdinatasun ez esanguratsua )</i></span><br />
<span style="color: red; font-family: Verdana, sans-serif;"><i>Garrantzizko odol jarioak %1.3 vs %2.2 AR 0.58(0.34-0.98)</i></span><br />
<span style="color: red; font-family: Verdana, sans-serif;"><i><br /></i></span>
<span style="color: red; font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">Emaitza hauek ikusita, iraupena erabakitzeko unean , onura eta kalteen arteko oreka garbi daukagula uste duzue?</span>Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-25552404688194950362017-06-30T12:16:00.001+02:002017-06-30T12:16:35.666+02:00EKAINA<ol>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28594069?dopt=Abstract" target="_blank">Diabetikoetan gluzemiaren kontrol intentsiboak ez du giltzurrun gutxiegitasuna, hilkortasuna edo gaixotasun kardiobaskularra gutxitzen ohiko kontrolarekin alderatuz.</a></li>
<li><a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009348.pub2/full" target="_blank">Kortikoideen infiltrazioa oin-zolako faszitisean ez da eraginkorra epe ertainean.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28116747" target="_blank">Pneumokokoaren aurkako txertoa biriketako gaixotasun buxatzaile kronikoa daukaten gaixoetan neumoniak eta exazerbazioak gutxitzen ditu.</a></li>
<li><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1607033" target="_blank">Azaleko abzesu txikietan antibiotikoa drainadurari gehitzen bazaio lehenago sendatzen dira.</a></li>
<li><a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000356.pub4/full" target="_blank">Etxeko ospitalizazioa ez da merkeagoa eta ez ditu osasun helburuak hobetzen.</a></li>
</ol>
Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-5657362788507421631.post-91788238478155724222017-05-01T10:48:00.000+02:002017-05-01T10:48:00.408+02:002017KO APIRILA<b><u>2017KO APIRILA.</u></b><br />
<br />
Hemendik aurrera argitalpen berrien laburpena hilero egingo dugu.<br />
<br />
<ol>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28418482" target="_blank">Antibiotikorik behar ez duten amigdalitis daukaten gaixoetan dexametasonak ez du mina arintzen lehenengo 24 orduetan.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28241154" target="_blank">Akupuntura eraginkorra izan daiteke migrainaren prebentzioan. </a></li>
<li><a href="http://www.cochrane.org/CD011748/VASC_pcsk9-inhibitors-prevention-cardiovascular-disease" target="_blank">PCSK9 inhibitzaileek gaixotasun kardiobaskularrak gutxitzen dituzte bainan ez hilkortasuna.</a></li>
<li><span style="font-family: inherit;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/28410791" target="_blank"><span style="font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12.8px;">Kardiobaskular arrisku handiko eta urdaileko odoljarioa edukitzeko arrisku handia daukaten gaixoetan,aspirinarekin eta <span style="font-family: 'Times New Roman'; font-size: small;">hantura-kontrako ez-esteroideekin </span>jarraitu behar badute,</span> zelekoxib gehi protoi ponpako inhibitzaile bat tratamentu egokiena da urdaileko odoljarioa saiesteko.</a></span></li>
</ol>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-6715314779828772772017-04-22T22:58:00.001+02:002017-04-22T22:58:31.209+02:00Erretzeari uzteko talde lana baliogarria da?<span style="font-family: Verdana, sans-serif;">Cochraneko labetik atera berri den <a href="https://www.ncbi.nlm.nih.gov/pubmed/28361497?dopt=Abstract&otool=icamculib" target="_blank">azterketa sistematiko honek </a> dionez, erretzeari uzteko taldeekin egiten diren esku-hartzeak eraginkorrak dira.</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">13 ikerketek diote, autolaguntzakin alderatuta hobe dela taldean egindako lana; lagun gehiagok uzten dute erretzeari alegia. AE 1.88(1.52-2.33) <a href="http://www.elsevier.es/es-revista-cirugia-espanola-36-articulo-sistema-grade-clasificacion-calidad-evidencia-S0009739X13003394" target="_blank">GRADE</a> sistemaren arabera, proben kalitatea erdi mailakoa dela diote.</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiRDl_yzU3EraBqfCk5O8PSQLmEKXe-ML636ubJd28UW3kpHGveWn9nN7nprPqO9JKbC3TLXIM3E82DZ1i9MSfl3hpljxzeJjHBJrRY4QXc0x-wF3SOnk_lyepDgTIhxEIbV1sc7OWLmec/s1600/El-grupo+%25281%2529.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" height="237" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiRDl_yzU3EraBqfCk5O8PSQLmEKXe-ML636ubJd28UW3kpHGveWn9nN7nprPqO9JKbC3TLXIM3E82DZ1i9MSfl3hpljxzeJjHBJrRY4QXc0x-wF3SOnk_lyepDgTIhxEIbV1sc7OWLmec/s320/El-grupo+%25281%2529.jpg" width="320" /></a><span style="font-family: Verdana, sans-serif;">Beste 14 ikerketek , osasun langileak emandako aholku motzarekin alderatu dute talde lana eta hau ere eraginkorragoa dela dirudi: AE 1.22(1.03-1.43) .</span><br />
<span style="font-family: Verdana, sans-serif;">Kasu honetan ebidentzia maila baxua dela diote. (heterogeneotasuna I2 =%59)</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">9 ikerketetatik datozen datuak, proben kalitatea oso eskasa bada ere, ezer ez egitea baina hobea omen da talde lana ere AE 2.60 (1.80-3.76)</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<span style="font-family: Verdana, sans-serif;">Taldeko lana eta bakarkako esku-hartze intentsiboaren artean ezberdintasunik ez dute topatu 6 ikerketan oinarrituta AE 0.99( 0.76-1.28) </span><br />
<br />
<br />Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-91715932470022861302017-04-07T15:21:00.000+02:002017-04-07T15:21:01.421+02:00HIPERTIROIDISMOAREN TRATAMENDUA <span style="font-family: "verdana" , sans-serif;"> Nere lankide batek Graves-Basedow gaixotasunaren ondorioz, larria ez den </span><span style="font-family: "verdana" , sans-serif;">hipertiroidismo</span><span style="font-family: "verdana" , sans-serif;"> dauka (ez exoftalmiarik, ezta tirotoxikotasunik).</span><br />
<span style="font-family: "verdana" , sans-serif;">Bi txandatan egin du antitiroideoekin tratamendua eta bietan normaldu egin ohi da baina handik denboraldi batera berritu egin zaio.</span><br />
<span style="font-family: "verdana" , sans-serif;">Egoera honen aurrean , endokrinoko espezialistak Iodo 131-arekin behin betiko tratamendua eskeini dio.</span><br />
<span style="font-family: "verdana" , sans-serif;">Bera, pozik dago <a href="https://www.aemps.gob.es/cima/dochtml/ft/24700/FichaTecnica_24700.html" target="_blank">METIMAZOL</a> hartuz eta tratmendua aldatzeak zalantzak sortzen dizkionez, galdetu egin dit.</span><br />
<br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjsOIZi_ZLheQY034PGEaS1sTgRwSBnzpbTN3tc8g-GtWipYRHhTpAngqh7EtnHj_n8dKALbAcvXuxta0rzTbDHX6RdDZ65khUA6g21HBaytgnf0y6HM6sO_0db4LpmWUlIlgvtAJFG9JE/s1600/hipotiroidismo.jpg" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="208" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjsOIZi_ZLheQY034PGEaS1sTgRwSBnzpbTN3tc8g-GtWipYRHhTpAngqh7EtnHj_n8dKALbAcvXuxta0rzTbDHX6RdDZ65khUA6g21HBaytgnf0y6HM6sO_0db4LpmWUlIlgvtAJFG9JE/s400/hipotiroidismo.jpg" width="400" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="http://www.laplazadealfaz.com/index.php?modules=Blog/ver_blog&id=36" target="_blank">Marrazkia hemendik lortu dugu </a></td></tr>
</tbody></table>
<br />
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"> </span><br />
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;"><br /></span>
<span style="font-family: "verdana" , sans-serif;">Up To date-n ederki laburtuta dago gaia</span> <a href="https://www.uptodate.com/contents/graves-hyperthyroidism-in-nonpregnant-adults-overview-of-treatment?source=search_result&search=hipertiroidismo&selectedTitle=3~150" target="_blank">,</a><span style="background-color: white; font-family: "arial" , "helvetica neue" , "helvetica" , sans-serif; font-size: 14.4px; font-weight: bold;"><a href="https://www.uptodate.com/contents/graves-hyperthyroidism-in-nonpregnant-adults-overview-of-treatment?source=search_result&search=hipertiroidismo&selectedTitle=3~150" target="_blank">Graves' hyperthyroidism in nonpregnant adults: Overview of treatment</a>,</span><span style="background-color: white; font-family: "arial" , "helvetica neue" , "helvetica" , sans-serif; font-size: 14.4px;"> atalean.</span><br />
<span style="background-color: white; font-family: "arial" , "helvetica neue" , "helvetica" , sans-serif; font-size: 14.4px;"><br /></span>
<span style="background-color: white; font-family: "arial" , "helvetica neue" , "helvetica" , sans-serif; font-size: 14.4px;">3 aukera ematen ditu : metimazolekin jarraitu denbora luzean , guruinaren ebakuntza edo Iodo 131. Guztiak dituzte alde onak eta ez hain onak ; edozein aukera onargarria denez , pazientearekin batera hartu beharko genuke erabakia. </span><br />
<span style="background-color: white; font-family: "arial" , "helvetica neue" , "helvetica" , sans-serif; font-size: 14.4px;"><a href="https://docs.google.com/document/d/1DfVUbiPak4Q0SNRjvZSKb3slOSJfVtc0q7HXICDLIIA/edit?usp=sharing" target="_blank">ikusi taula</a></span><br />
<span style="background-color: white; font-family: "arial" , "helvetica neue" , "helvetica" , sans-serif; font-size: 14.4px;"><br /></span>
<span style="background-color: white; font-family: "arial" , "helvetica neue" , "helvetica" , sans-serif; font-size: 14.4px;"><br /></span>
<span style="background-color: white; font-family: "arial" , "helvetica neue" , "helvetica" , sans-serif; font-size: 14.4px;"><br /></span>
<div class="cntnt" style="border-bottom: 2px solid rgb(0, 153, 102); border-top: 5px solid rgb(0, 153, 102); display: inline-block; font-family: Verdana, Geneva, sans-serif; font-size: 16px; margin: 0em; padding: 0em 0.625em; text-align: center;">
<div id="graphics-copyright" ng-hide="graphicCtrl.tools.isPrintView" style="background-color: white; font-family: "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 0.8em; margin: 0px; padding: 1em 1.2em 0px; text-align: start;" utd-copyright="">
<div id="graphics-copyright" ng-hide="graphicCtrl.tools.isPrintView" style="font-size: 0.8em; margin: 0px; padding: 1em 1.2em 0px;" utd-copyright="">
<br /></div>
</div>
</div>
Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-49632271255221867542017-04-02T09:12:00.001+02:002017-04-02T09:12:27.903+02:002017ko 13. ASTEA<ol>
<li><a href="http://www.cochrane.org/CD010134/ANAESTH_continuous-chest-compression-versus-interrupted-chest-compression-cardiopulmonary-resuscitation-cpr" target="_blank">Bihotzeko geldialdian bularreko konpresioak etengabe egin behar dira, aireztatzeko gelditu gabe.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Intradiscal+Glucocorticoid+Injection+for+Patients+With+Chronic+Low+Back+Pain+Associated+With+Active+Discopathy%3A+A+Randomized+Trial" target="_blank">Lunbalgia kronikoan glukokortikoideko injekzio bat diskaren barruan hilabeteko epean mina gutxitzen du bainan ez urte bateko epean.</a></li>
</ol>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-64324543394700806642017-03-27T07:42:00.001+02:002017-03-27T07:42:53.339+02:00<u>2017ko martxoaren 20tik 26ra doan astea.</u><br />
<br />
<ol>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28288249?dopt=Abstract" target="_blank">Giltzurruneko gaixotasun kronikoa duten gaixoetan tentsio arteriala 130/90tik jaisteak ez dakar onurarik ohiko kontrolarekin alderatuz. </a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/28271513?dopt=Abstract" target="_blank">Dispepsia funtzionalean protoizko ponparen inhibitzaileak, bi astetik zortzi asteko iraupenarekin, plazebo baino zertxobait eraginkorragoak dira. </a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Trial+of+Pregabalin+for+Acute+and+Chronic+Sciatica" target="_blank">Pregabalina ez da eraginkorra ziatikan.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/27918778" target="_blank">Hilzorian dauden gaixoetan haloperidolak eta risperidonak delirioko sintomak handitzen dituzte eta haloperidolak hilkortasuna handitzen du.</a></li>
</ol>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-2847452280641724092017-03-23T12:38:00.000+01:002017-03-23T12:38:05.327+01:00RENINA –ANGIOTENSINA INIBITZAILEAK ERABILTZEN HASTEN GARENEAN. KREATININAREN IGOERAK GARRANTZIRIK BA OTE? <div dir="ltr" style="text-align: left;" trbidi="on">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><br />
<!--[if gte mso 9]><xml>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves>false</w:TrackMoves>
<w:TrackFormatting/>
<w:HyphenationZone>21</w:HyphenationZone>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>ES</w:LidThemeOther>
<w:LidThemeAsian>X-NONE</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="267">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Tabla normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0cm;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-fareast-language:EN-US;}
</style>
<![endif]-->
<br />
<div class="MsoNormal">
<span style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"></span><span style="mso-spacerun: yes;"> </span>Gaur arte jakina da,
renina- angiotensina inibitzaileekin tratamendua hastean kreatinina maila igo ditekeela
(nahiz eta ez den arrunta), eta kalterik ez sortzeko<span style="mso-spacerun: yes;"> </span>(heriotzak, bihotz gutxitasuna, miokardio
infartuak, giltzurrun gutxitasuna) <span style="mso-spacerun: yes;"> </span>segurtasun
muga %30eko igoeran dagoela.</div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<br /></div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; text-align: center;"><tbody>
<tr><td style="text-align: center;"><img alt="" src="data:image/png;base64,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" style="margin-left: auto; margin-right: auto;" /> </td></tr>
<tr><td class="tr-caption" style="text-align: center;">cardioclinico tik hartuta</td></tr>
</tbody></table>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Erresuma<span style="mso-spacerun: yes;"> </span>Batuan egindako <a href="http://www.bmj.com/content/bmj/356/bmj.j791.full.pdf">Kohorte Ikerketa</a>
<span style="mso-spacerun: yes;"> </span>honek nolabait erakusten digu, <span style="mso-spacerun: yes;"> </span>kreatinina mailaz- maila (%10) igotzeak (ez
bakarrik %30eko muga gainditzea), miokardioko infartuak, bihotz gutxitasuna,
giltzurrun gutxitasuna eta heriotzak<span style="mso-spacerun: yes;">
</span>gehitzen dituela.</div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Kreatininaren %30eko<span style="mso-spacerun: yes;">
</span>gorakada baino gehiago izateko arrisku faktore <span style="mso-spacerun: yes;"> </span>hauek aipatzen dituzte: Emakume izateak, giltzurrun gutxitasun aurreratua, aldez aurretik <span style="mso-spacerun: yes;"> </span>miokardio infartua,<span style="mso-spacerun: yes;"> </span>bihotz gutxitasuna, gaisotasun arteriala
izateak, asako diuretikoak, beta blokeatzaileak, eta antiinflamatorioak,
hartzeak<span style="mso-spacerun: yes;"> </span>.</div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
Azkenik aipagarria, kreatinina %30eko <span style="mso-spacerun: yes;"> </span>gorakada izan dutenen artean, %80ak
medikamentuakin jarraitzen zuen.</div>
<div class="MsoNormal">
<br /></div>
</div>
martahttp://www.blogger.com/profile/02438075319798462813noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-59356242659600849642017-03-21T14:39:00.000+01:002017-03-22T12:09:46.310+01:00Hatzetako tendoien haustura Beti zalantza berdina sortzen zait hatzetako tendoiaren haustura ikustea suertazten zaidanean ..zein da joskura ahal den azkarren egin behar zaiona ? tendoi hedatzaile edo tolestzaileari?<br />
<br />
Up To date-n eranztuna minutu pare batean lortu dut<br />
<br />
<b>TENDOI TOLESTATZAILEAREN HAUSTURA : Traumatologoak azkar aztertu dezan bideratu behar dugu </b><br />
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<i><span style="font-size: x-small;">Jersey finger is an acute rupture of the flexor digitorum profundus (FDP) tendon at its insertion at the distal phalanx. The tendon may retract to the proximal interphalangeal joint or all the way to the palm. </span></i></div>
<div style="background-color: white; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 0.9em; margin-top: 0.9em;">
</div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span class="glyph" style="left: -17px; position: absolute;"><i><span style="font-size: x-small;">●</span></i></span><i><span style="font-size: x-small;">Rupture of the FDP is caused by a sudden, forceful hyperextension of the distal interphalangeal (DIP) joint. </span></i></div>
<div style="background-color: white; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 0.9em; margin-top: 0.9em;">
</div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span class="glyph" style="left: -17px; position: absolute;"><i><span style="font-size: x-small;">●</span></i></span><i><span style="font-size: x-small;">Examination findings with jersey finger injuries include pain and swelling at the palmar DIP joint or along the volar aspect of the involved finger and inability to flex the DIP joint.</span></i></div>
<div style="background-color: white; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 0.9em; margin-top: 0.9em;">
</div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span class="glyph" style="left: -17px; position: absolute;"><i><span style="font-size: x-small;">●</span></i></span><i><span style="font-size: x-small;"><span style="color: red;">ALL jersey finger injuries should be referred urgently</span> <span style="color: red;">to a hand surgeon</span>. <span style="color: red;">Definitive treatment is surgical in all cases, and some injuries require surgical repair within 7 to 10 days.</span></span></i></div>
<div style="background-color: white; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 0.9em; margin-top: 0.9em;">
</div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span class="glyph" style="left: -17px; position: absolute;"><i><span style="font-size: x-small;">●</span></i></span><i><span style="font-size: x-small;">Jersey finger may be misdiagnosed initially as a "sprained finger" or present late if a patient does not appreciate the extent of injury. Complications are more likely with late presentations. </span></i></div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span style="font-size: 14.4px;"><br /></span></div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span style="font-size: 14.4px;"><b>TENDOI HEDATZAILEAREN HAUSTURA : 6-8 astetan hatza hedatua eduki behar da ferula bidez eta ezbada erabat osatu, beste 2 astetan gauean jarri ferula </b></span></div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span style="font-size: 14.4px;"><i><br /></i></span></div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<i>Mallet finger injuries are the result of a partial or complete rupture of the extensor tendon's <table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEis201KNgk7eeb5LoDKSQOZHWmqf2p2aADKn4xC6cH6wYx29YZzAZm6BGTCyeDx7B6b3oT_wYokjAqAj49rSkDogDRi4_TjAmft7q72-6ZH_aZlbd6wzDCCaM21tYxENtbgDx1sRNIx2J4/s1600/Dedo-roto-ortop%2526eacute.jpg" imageanchor="1" style="clear: left; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" height="200" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEis201KNgk7eeb5LoDKSQOZHWmqf2p2aADKn4xC6cH6wYx29YZzAZm6BGTCyeDx7B6b3oT_wYokjAqAj49rSkDogDRi4_TjAmft7q72-6ZH_aZlbd6wzDCCaM21tYxENtbgDx1sRNIx2J4/s200/Dedo-roto-ortop%2526eacute.jpg" width="199" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><a href="https://es.aliexpress.com/popular/tendons-finger.html" target="_blank">Web honetatik atera dugu argazkia</a> </td></tr>
</tbody></table>
terminal insertion distal to the distal interphalangeal (DIP) joint. They are caused by a forced flexion injury.</i></div>
<div style="background-color: white; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 0.9em; margin-top: 0.9em;">
</div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span class="glyph" style="left: -17px; position: absolute;"><i>●</i></span><i>Examination findings in a mallet finger injury include pain and swelling over the dorsum of the DIP joint, a DIP flexor deformity, and an inability to actively extend the DIP joint.</i></div>
<div style="background-color: white; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 0.9em; margin-top: 0.9em;">
</div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span class="glyph" style="left: -17px; position: absolute;"><i>●</i></span><i>Surgical referral should be obtained if the mallet finger is associated with a fracture, the DIP joint cannot be passively extended, or there is DIP joint subluxation.</i></div>
<div style="background-color: white; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 0.9em; margin-top: 0.9em;">
</div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span class="glyph" style="left: -17px; position: absolute;"><i>●</i></span><i><span style="color: red;">We suggest that uncomplicated mallet finger injuries be treated by maintaining the DIP joint in full extension or minimally hyperextended using an appropriate splint (<a class="grade" href="https://www.uptodate.com/contents/grade/6?title=Grade%202C&topicKey=SM/198" style="background-color: transparent; font-weight: 700;">Grade 2C</a>). It is crucial that patients not allow flexion of the DIP at any time during the initial period of splinting (generally six to eight weeks).</span></i></div>
<div style="background-color: white; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 0.9em; margin-top: 0.9em;">
</div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<span class="glyph" style="left: -17px; position: absolute;"><i>●</i></span><i>DIP splinting is performed continuously for six to eight weeks. If no extensor lag exists at the end of this period, <span style="color: red;">night splinting is then performed for two additional weeks.</span></i></div>
<div class="bulletIndent1" style="background-color: white; clear: both; font-family: Arial, "Helvetica Neue", Helvetica, sans-serif; font-size: 14.4px; line-height: 20.16px; margin-bottom: 2px; margin-left: 2em; margin-top: 2px; position: relative;">
<br /></div>
Inahttp://www.blogger.com/profile/06593470303422086659noreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-87771957794578025592017-03-19T21:41:00.000+01:002017-03-20T08:00:22.725+01:00<h2>
<b><u>2017ko martxoaren 13tik 19ra doan asteko argitalpen berriak.</u></b></h2>
<div>
Aste hau ez da oso emankorra izan:</div>
<ol>
<li><a href="http://www.cochrane.org/CD006887/VASC_clinical-effects-cardiovascular-risk-scores-people-without-cardiovascular-disease" target="_blank">Arrisku kardiobaskularra kalkulatzeak, aurretik gaixotasuna ez duten pertsonetan, ez ditu gaixotasun kardiobaskularrak gutxitzen.</a></li>
<li> <a href="https://www.ncbi.nlm.nih.gov/pubmed/28187918?dopt=Abstract" target="_blank">Diazepam ez da eraginkorra </a><a href="https://www.ncbi.nlm.nih.gov/pubmed/28187918?dopt=Abstract" target="_blank">naproxenori </a><a href="https://www.ncbi.nlm.nih.gov/pubmed/28187918?dopt=Abstract" target="_blank">gehitzen zaionean lunbalgietan.</a></li>
</ol>
Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-5657362788507421631.post-22634158316825307072017-03-13T09:17:00.002+01:002017-03-13T09:17:33.785+01:00ASTEKO BERRIAK<h2>
</h2>
<h2>
<u>2017KO MARTXOAREN 6TIK 12RA.</u></h2>
<div>
<br />
<span style="font-weight: normal;">Atal berri bat sortuko dugu. Astean zehar sortzen diren argitalpen interesgarrien laburpenak argitaratuko ditugu.</span><br />
<span style="font-weight: normal;"><br /></span></div>
<h3>
Pasa den astean ikerketa hauek interesgarriak iruditu zaizkigu:</h3>
<div>
<ol>
<li><div style="background-color: white; box-sizing: border-box; color: #222222; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 26px; margin-bottom: 26px;">
<b style="box-sizing: border-box;">Kasu-kontrolezko ikerketa <a href="http://jamanetwork.com/journals/jamaneurology/fullarticle/2606444?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamaneurol.2016.5704" target="_blank">honetan</a> garun hodietako istripua migrainarekin erlazionatzen da. Asoziazioa handiagoa da 40 urte azpiko pertsonetan, gizonezkoetan eta migraina aurarik gabekoetan.</b></div>
</li>
<li><div style="background-color: white; box-sizing: border-box; color: #222222; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 26px; margin-bottom: 26px;">
<b><a href="http://scemergentziak.blogspot.com.es/2017/03/que-solucion-antiseptica-es-la-mas.html" target="_blank">Alkohola + klorexidina antiseptiko egokienak dira zain bat zulatu aurretik.</a></b></div>
</li>
<li><div style="background-color: white; box-sizing: border-box; color: #222222; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 26px; margin-bottom: 26px;">
<b><a href="http://www.cochrane.org/CD009868/VASC_fixed-dose-combination-drug-therapy-prevention-heart-disease-and-stroke" target="_blank">Dosi finkoa pilula berean bihotz eta garun hodietako gaixotasuna ekiditeko</a>. Cochrane ikerketa honetan ezin izan da frogatu pilula berean elkarturiko botikek bihotz eta garun hodietako gaixotasunak ekiditen direnik.</b></div>
</li>
<li><div style="background-color: white; box-sizing: border-box; color: #222222; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 26px; margin-bottom: 26px;">
<b><a href="http://www.2minutemedicine.com/despite-guidelines-pediatricians-vary-in-antibiotic-choice-for-pneumonia/" target="_blank">Nahiz eta gidek amoxizilina gomendatu, pediatrek makrolidoak erabiltzen dituzte neumoniak tratatzeko.</a></b></div>
</li>
<li><div style="background-color: white; box-sizing: border-box; color: #222222; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 26px; margin-bottom: 26px;">
<b><a href="http://www.cochrane.org/CD011761/PREG_iodine-supplementation-women-during-or-after-pregnancy" target="_blank">Ezin da frogatu iodoa haurdunaldi inguruan erangikorra denik haurren hipotiroidismoa ekiditeko.</a></b></div>
</li>
<li><div style="background-color: white; box-sizing: border-box; color: #222222; font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif; font-size: 15px; line-height: 26px; margin-bottom: 26px;">
<b><a href="http://scemergentziak.blogspot.com.es/2017/03/cuanto-tiempo-se-pueden-mantener.html" target="_blank">Gluzemia aztertzeko tirak kutxa ireki eta gero 3 hilabetez bakarrik fidagarriak dira.</a></b></div>
</li>
</ol>
</div>
Unknownnoreply@blogger.com0